Biopolym. Cell. 1995; 11(2):5-14.
http://dx.doi.org/10.7124/bc.0003DB
Науково-практичне використання гемопоетичних клітин кордової крові
1Кухаренко О. П., 2Когут Г. І., 1Швед А. Д.
  1. Інститут молекулярної біології і генетики НАН України
    Вул. Академіка Заболотного, 150, Київ, Україна, 03680
  2. Київський НДІ гематології та переливання крові МОЗ України
    вул. Максима Берлинського, 12., Київ, Україна, 252060

Abstract

В огляді наведено літературні дані стосовно виникнення і розвитку ідеї використання пуповинної, або кордової, крові (КК) як альтернативного джерела стовбурових гемопоетичних клітин для трансплантації пацієнтам з порушеннями власного кроветво­рения. Розглядаються також результати експериментальних досліджень трансдукції геноінженерних векторних конструкцій до кровотворних клітин КК для подальшого їх використання в генній терапії і біотехнології.
Із області цитологічних досліджень подано якісні і кількісні характеристики ди­ференційованого потомства іпопередників кроветворения за умов їх коротко- та дов­гострокового культивування, що свідчить про суттєву перевагу КК перед кістковим мозком (KM) при застосуванні для трансплантацій реципієнтам з дефектами гемопоезу. Сума наукових, методичних і технічних даних підтверджує можливість створення національних банків КК, які з часом замінять існуючі на сьогодні регістри донорів KM.
Повний текст: (PDF, російською)

References

[1] Linch DC, Brent L. Marrow transplantation. Can cord blood be used? Nature. 1989;340(6236):676.
[2] Alper J. Two firms tackle cord–blood transplants. Bio/Technology. 1994;12(1):23–4.
[3] Howard MR, Hows JM, Gore SM, Barrett J, Brenner MK, Goldman JM, Gordon-Smith EC, Poynton C, Prentice HG, Whittaker JA, et al. Unrelated donor marrow transplantation between 1977 and 1987 at four centers in the United Kingdom. Transplantation. 1990;49(3):547-53.
[4] Beatty PG, Hansen JA, Longton GM, Thomas ED, Sanders JE, Martin PJ, Bearman SI, Anasetti C, Petersdorf EW, Mickelson EM, et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation. 1991;51(2):443-7.
[5] Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D, Arny M, Thomas L, Boyse EA. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86(10):3828-32.
[6] Broxmeyer HE, Hangoc G, Cooper S, Ribeiro RC, Graves V, Yoder M, Wagner J, Vadhan-Raj S, Benninger L, Rubinstein P, et al. Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A. 1992;89(9):4109-13.
[7] Broxmeyer HE, Hangoc G, Cooper S. Clinical and biological aspects of human umbilical cord blood as a source of transplantable hematopoietic stem and progenitor cells. Bone Marrow Transplant. 1992;9 Suppl 1:7-10. Review.
[8] Harris DT, Schumacher MJ, Locascio J, Besencon FJ, Olson GB, DeLuca D, Shenker L, Bard J, Boyse EA. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci U S A. 1992;89(21):10006-10.
[9] Cardoso AA, Li ML, Batard P, Hatzfeld A, Brown EL, Levesque JP, Sookdeo H, Panterne B, Sansilvestri P, Clark SC, et al. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci U S A. 1993;90(18):8707-11.
[10] Heyworth CM, Vallance SJ, Whetton AD, Dexter TM. The biochemistry and biology of the myeloid haemopoietic cell growth factors. J Cell Sci Suppl. 1990;13:57-74.
[11] Inouye M. Antisense RNA: its functions and applications in gene regulation--a review. Gene. 1988;72(1-2):25-34.
[12] Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 1988;48(10):2659-68.
[13] Vilmer E, Sterkers G, Rahimy C, Denamur E, Elion J, Broyart A, Lescoeur B, Tiercy JM, Gerota J, Blot P. HLA-mismatched cord-blood transplantation in a patient with advanced leukemia. Transplantation. 1992;53(5):1155-7.
[14] Wagner JE, Broxmeyer HE, Byrd RL, Zehnbauer B, Schmeckpeper B, Shah N, Griffin C, Emanuel PD, Zuckerman KS, Cooper S, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79(7):1874-81.
[15] Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, Esperou H, Thierry D, Socie G, Lehn P, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-8.
[16] Gluckman E, Devergie A, Thierry D, Esperou-Bourdeau H, Traineau R, Gerrota J, Brossard Y, van Nifterik J, Benbunan M. Clinical applications of stem cell transfusion from cord blood and rationale for cord blood banking. Bone Marrow Transplant. 1992;9 Suppl 1:114-7.
[17] Vowels MR, Tang RL, Berdoukas V, Ford D, Thierry D, Purtilo D, Gluckman E. Brief report: correction of X-linked lymphoproliferative disease by transplantation of cord-blood stem cells. N Engl J Med. 1993;329(22):1623-5.
[18] Harris DT. Cord blood transplantation: past, present and future. Clin Res. News for Arisona Physicians. 1994; 5(1):90.
[19] Hows JM, Bradley BA, Marsh JC, Luft T, Coutinho L, Testa NG, Dexter TM. Growth of human umbilical-cord blood in longterm haemopoietic cultures. Lancet. 1992;340(8811):73-6.
[20] Hows JM, Marsh JC, Bradley BA, Luft T, Coutinho L, Testa NG, Dexter TM. Human cord blood: a source of transplantable stem cells? Bone Marrow Transplant. 1992;9 Suppl 1:105-8.
[21] Clay TM, Bidwell JL, Howard MR, Bradley BA. PCR-fingerprinting for selection of HLA matched unrelated marrow donors. Collaborating Centres in the IMUST Study. Lancet. 1991;337(8749):1049-52.
[22] Betuel H, Gebuhrer L, Souillet G, Philippe N. HLA typing by serology and by molecular biology of fetal and cord-blood cells. Bone Marrow Transplant. 1992;9 Suppl 1:60-3.
[23] Thierry D, Hervatin F, Traineau R, Brossard Y, Stark R, Benbunan M, Gluckman E. Hematopoietic progenitors cells in cord blood. Bone Marrow Transplant. 1992;9 Suppl 1:101-4.
[24] Charbord P, Newton I, Schaal JP, Herve P. The separation of human cord blood by density gradient does not induce a major loss of progenitor cells. Bone Marrow Transplant. 1992;9 Suppl 1:109-10.
[25] Pahwa RN, Fleischer A, Than S, Good RA. Successful hematopoietic reconstitution with transplantation of erythrocyte-depleted allogeneic human umbilical cord blood cells in a child with leukemia. Proc Natl Acad Sci U S A. 1994;91(10):4485-8.
[26] Moritz T, Keller DC, Williams DA. Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease. J Exp Med. 1993;178(2):529-36.
[27] Lu L, Xiao M, Clapp DW, Li ZH, Broxmeyer HE. High efficiency retroviral mediated gene transduction into single isolated immature and replatable CD34(3+) hematopoietic stem/progenitor cells from human umbilical cord blood. J Exp Med. 1993;178(6):2089-96.
[28] Touraine JL. In utero transplantation of fetal liver stem cells in humans. Blood Cells. 1991;17(2):379-87.
[29] Raudrant D, Touraine JL, Rebaud A. In utero transplantation of stem cells in humans: technical aspects and clinical experience during pregnancy. Bone Marrow Transplant. 1992;9 Suppl 1:98-100.
[30] Touraine JL, Raudrant D, Rebaud A, Roncarolo MG, Laplace S, Gebuhrer L, Betuel H, Frappaz D, Freycon F, Zabot MT, et al. In utero transplantation of stem cells in humans: immunological aspects and clinical follow-up of patients. Bone Marrow Transplant. 1992;9 Suppl 1:121-6.
[31] Lansdorp PM, Dragowska W, Mayani H. Ontogeny-related changes in proliferative potential of human hematopoietic cells. J Exp Med. 1993;178(3):787-91.
[32] Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97-129.
[33] Nahreini P, Woody MJ, Zhou SZ, Srivastava A. Versatile adeno-associated virus 2-based vectors for constructing recombinant virions. Gene. 1993;124(2):257-62.
[34] Chatterjee S, Johnson PR, Wong KK Jr. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science. 1992;258(5087):1485-8.
[35] Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci U S A. 1992;89(15):7257-61.
[36] Ponnazhagan S, Nallari ML, Srivastava A. Suppression of human alpha-globin gene expression mediated by the recombinant adeno-associated virus 2-based antisense vectors. J Exp Med. 1994;179(2):733-8.
[37] Zhou SZ, Cooper S, Kang LY, Ruggieri L, Heimfeld S, Srivastava A, Broxmeyer HE. Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med. 1994;179(6):1867-75.
[38] Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, Porta F, Griscelli C, Goldman SF, Levinsky R, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet. 1990;336(8719):850-4.
[39] Bacchetta R, Vandekerckhove BA, Touraine JL, Bigler M, Martino S, Gebuhrer L, de Vries JE, Spits H, Roncarolo MG. Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells. J Clin Invest. 1993;91(3):1067-78.
[40] Bacchetta R, Bigler M, Touraine JL, Parkman R, Tovo PA, Abrams J, de Waal Malefyt R, de Vries JE, Roncarolo MG. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179(2):493-502.
[41] Sakaguchi N, Miyai K, Sakaguchi S. Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J Immunol. 1994;152(5):2586-95.
[42] Sukhikh GT, Molnar EM, Malaĭtsev VV, Bogdanova IM. Transplantation of human fetal tissues in hematology. Biull Eksp Biol Med. 1994;117(4):375-7.
[43] Gale RP. Fetal liver transplants. Bone Marrow Transplant. 1992;9 Suppl 1:118-20.
[44] Koshland DE Jr. Fetal tissue research. Science. 1992;256(5065):1741.
[45] Palca J. Fetal tissue. Banking for transplantation research. Science. 1992;256(5061):1274.
[46] Culliton BJ. Needed: fetal tissue research. Nature. 1992;355(6358):295.
[47] US muddles policy on fetal tissue. Nature. 1992;358(6382):93.
[48] Bianchi DW, Bernfield M, Nathan DG. A revived opportunity for fetal research. Nature. 1993;363(6424):12.
[49] Anderson C. Healy stays, fetal tissue ban goes. Science. 1993;259(5095):591.
[50] Using fetal tissue. Nature. 1989;340(6232):327-8.
[51] Edwards RG. Human embryo as a source of cells. Bone Marrow Transplant. 1992;9 Suppl 1:90-2.
[52] Corliss J. Umbilical cord blood may be lifeline for some patients. J Natl Cancer Inst. 1993;85(14):1107-8.
[53] Banking on Umbilical Cords. Science. 1992;257(5070):615.
[54] Leibovit M. Cryo-cell international, Inc. The Volume Reversal Survey (June 29, 1990).